Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ISRCTN17037497) titled 'A study of JNJ-95804306 for relapsed or refractory hematological malignancies' on June 15.
Study Type: Interventional
Study Design:
Allocation: Non-randomized controlled trial
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Safety
Primary Sponsor: Janssen-Cilag International NV
Condition:
Hematologic neoplasms, blood cancer
Cancer
Intervention:
Arm A: R/R Acute Myeloid Leukaemia (AML)/ High-Risk Myelodysplastic Syndrome (HR MDS)
Participants with relapsed/refractory (R/R) AML/HR-MDS will receive JNJ-95804306 monotherapy (Arm A1) or as an addition to standard of care (SoC)...